


TCV-309 chloride

Cat. No.:	HY-19121A
CAS No.:	121494-09-5
Molecular Formula:	C ₃₀ H ₃₄ BrClN ₄ O ₄
Molecular Weight:	629.97
Target:	Platelet-activating Factor Receptor (PAFR)
Pathway:	GPCR/G Protein
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.3 mg/mL (10.00 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.5874 mL	7.9369 mL	15.8738 mL
	5 mM	0.3175 mL	1.5874 mL	3.1748 mL
	10 mM	0.1587 mL	0.7937 mL	1.5874 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

TCV-309 chloride is a potent and specific platelet activating factor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC₅₀ values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock^{[1][2]}.

In Vivo

In rats, TCV-309 selectively inhibits the PAF-induced hypotension, hemoconcentration and death with ED₅₀ values of 2.7, 6.4 and 1.7 micrograms/kg (i.v.), respectively. TCV-309 most potently protects mice from death induced by PAF and due to anaphylactic shock with ED₅₀ values of 2.1 and 2.6 micrograms/kg (i.v.), respectively^[1]. TCV-309 chloride also reversed PAF-induced hypotension and endotoxin-induced hypotension in rats with ED₅₀ values of 3.3 and 1.2 micrograms/kg (i.v.), respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Terashita Z et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260(2):748-55.

[2]. M Poeze, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14(4):421-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA